In addition, CCL2 and IL-16 produced by MSCs have been shown to influence the survival of cancer cells in many types of cancer, including hematological malignancies [121, 122], and their plasma levels were found to be elevated in AML and other hematological malignancies patients [121, 123]. Here, IL16 is linked to hematologic disorder.